Date: Jul 18, 2013 Source: Business Wire (
click here to go to the source)
SAN FRANCISCO--(BUSINESS WIRE)--BetaStem Therapeutics, Inc., a pre-clinical biotechnology company focused on a curative treatment for diabetic retinopathy and diseases related to vascular damage, has retained Conditas Biotechnology Group, LLC for its services in the area of business development and corporate strategy.